NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Metformin in Parkinson's Disease: Safety and Efficacy
Metformin in Parkinson's Disease: Safety and Efficacy

NCT07806019

Not Yet RecruitingPhase 4

Sponsor: Jinnah Medical & Dental College

Conditions: Parkinsons Disease (PD)

Interventions: Metformin 500mg

This study will evaluate whether metformin when it will be given to patients with Parkinson's disease along with standard therapy (levodopa carbidopa) will improve motor symptoms and decreases levels of alpha synuclein and MDA in patients with PD as compare to PD patients receiving only standard therapy (levodopa carbidopa)

Eligibility overview

Sex: ALL

Age: 50 Years to 70 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria: :

Male and female patients diagnosed with primary PD age 50-70 years receiving levodopa + carbidopa. Diagnosis will be made in accordance with movement disorder society clinical diagnostic criteria for Parkinson's disease

Exclusion Criteria:

Secondary Parkinsonism co-morbid (such as Diabetes mellitus, Cardio-vascular diseases, Senile tremors, Wilson's disease, Cancers etc.) Pregnant and lactating mothers Sensitivity to metformin Lactic acidosis History of alcohol use